Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors.
V. M. Santana
No relevant relationships to disclose
S. D. Baker
No relevant relationships to disclose
B. McCarville
Research Funding - GE Healthcare
C. F. Stewart
No relevant relationships to disclose
J. Wu
No relevant relationships to disclose
C. Billups
No relevant relationships to disclose
S. L. Spunt
No relevant relationships to disclose
W. L. Furman
No relevant relationships to disclose
L. M. McGregor
No relevant relationships to disclose
S. Hu
No relevant relationships to disclose
J. C. Panetta
No relevant relationships to disclose
W. E. Reddick
No relevant relationships to disclose
A. Davidoff
No relevant relationships to disclose
W. H. Leung
No relevant relationships to disclose
F. Navid
No relevant relationships to disclose